Wednesday, September 30, 2015

Cell therapy companies must improve internal process development

By Brian Caine 
Michael Paglia, senior director of technical operations at Bluebird Bio, told attendees at Cell Therapy Bioprocessing & Commercialization that companies need to “better understand the evolution of the process”.

Paglia told a packed session on viral production that there is a “significant need to determine how to improve their internal process development”.

He reviewed a specific case focusing on the downstream process development of a lentiviral vector and how one company offset product loss in their downstream process.

Companies must also have “proven tech-transfer in order to ensure proper reproducibility whether the process is internal or outsourced”, he said.

Join the conversation on Twitter by following #IBC_CTB15

Share this article with your social network, just click below to share now!

No comments :

Post a Comment